新诺威：拟购买巨石生物29%股权

Group 1 - The company Xinnoway (300765.SZ) signed a share transfer agreement with Enbipu Pharmaceutical to acquire a 29% stake in Jushi Biotech for a cash consideration of 1.1 billion yuan, increasing its ownership from 51% to 80% [1] - The transaction is based on an asset evaluation report from a qualified institution in accordance with the Securities Law [1] Group 2 - Jushi Biotech is an innovative biopharmaceutical company focused on antibody drugs, antibody-drug conjugates (ADC), and mRNA vaccines, with a strong emphasis on independent research and development [2] - The company has established a competitive R&D system and a promising product pipeline, covering three major therapeutic areas: oncology, autoimmune diseases, and major infectious diseases [2] - Jushi Biotech has numerous projects in development, with key products like Enlansumab and Omabuzumab set to launch in 2024, and several others in critical clinical trial phases [2] - The company has become a benchmark in the domestic monoclonal antibody and ADC innovation drug industry, providing safe, effective, and accessible biotherapy solutions globally [2] - Jushi Biotech is one of the first domestic companies to achieve mRNA vaccine industrialization and has a comprehensive layout in ADC and monoclonal antibody pipelines [2]